TL;DR: The DEA’s administrative review of cannabis rescheduling to Schedule III under the Controlled Substances Act entered a new phase this week as the Department of Justice’s Office of Legal Counsel completed its secondary review of the proposed rule, with the Federal Register publication of a final determination now expected in the September–October 2026 window according to sources familiar with the rulemaking timeline. A Schedule III classification would not legalize cannabis under federal law but would deliver the most consequential structural change to cannabis company economics in US history — specifically the elimination of IRC 280E disallowance, which currently forces multi-state operators to pay effective tax rates ranging from 60% to 90% of pre-tax income. Monitor cannabis equity market response to rescheduling developments on the Weedstock tracker.
Market Analysis
Cannabis equity markets opened Thursday’s session with modest positive bias as renewed rescheduling timeline optimism filtered through the sector following reporting from several financial news outlets indicating the Department of Justice review process has advanced further than previously disclosed. The MSO index — an informal tracking basket of the top eight multi-state operators by market capitalization — traded up approximately 2.3% in Thursday’s pre-market session, with Curaleaf (CURLF), Green Thumb Industries (GTBIF), and Trulieve (TCNNF) leading gainers on elevated volume.
The market reaction reflects institutional positioning dynamics that have built through the second half of 2026. Following the DEA’s initial Notice of Proposed Rulemaking in May 2024 and the subsequent administrative law judge hearing process that extended through early 2025, the rescheduling pathway has been materially longer than most market participants originally modeled. Operators, investors, and cannabis industry organizations have adjusted their probability frameworks accordingly — with the sector now broadly pricing in a 70–75% probability of Schedule III finalization by year-end 2026, based on implicit options market data.
The earnings impact math is straightforward and substantial. For a mid-size MSO generating $400 million in gross profit annually and currently paying an effective 280E-driven tax rate of 75%, a Schedule III classification restoring standard IRC deductibility would reduce the effective tax rate toward the 25–28% range applicable to comparable non-cannabis companies. The after-tax income conversion improvement — roughly $200 million annually at that revenue level — would represent an immediate and permanent earnings quality transformation. For the largest operators, the improvement runs into the $300–$400 million annual range, changes that would mechanically make several currently loss-generating cannabis companies profitable on a GAAP basis in the first reporting period following rescheduling.
Regulatory and Market Context
Understanding the current regulatory moment requires distinguishing between what Schedule III does and does not change. The proposed reclassification addresses only the federal scheduling status under the CSA — it does not establish a federal legal cannabis market, does not preempt state cannabis regulations, and does not resolve cannabis companies’ inability to access traditional banking services under the Bank Secrecy Act. The SAFER Banking Act, which would create a federal safe harbor for financial institutions serving cannabis businesses, remains stalled in the Senate despite passage in the House for the fourth consecutive congressional session.
What Schedule III does accomplish is the resolution of 280E — and that single change is sufficient to justify significant re-rating of cannabis equity valuations. Analysts at several financial institutions covering the sector have published scenario models indicating that Schedule III finalization without any other concurrent policy change would be sufficient to move the sector’s aggregate market capitalization by an estimated $8–$15 billion, depending on which discount rate and terminal value assumptions are applied to the after-tax cash flow improvement.
The current OLC review is a procedural step that the proposed rule requires given cannabis’s existing Schedule I status and the political salience of the change. The Office of Legal Counsel is examining whether the DEA’s administrative findings supporting Schedule III classification are legally defensible under the CSA’s eight-factor scheduling criteria. Legal experts tracking the process note that the OLC’s review has been notably thorough — the extended timeline is not generally interpreted as indicative of legal deficiency in the proposed rule, but rather reflects the historical significance of the determination and the scrutiny applied to any action that could be subject to judicial challenge.
International context adds another layer of relevance for LP-focused investors. The German recreational cannabis market, now operational since April 2024, continues to attract Canadian licensed producer investment — with OrganiGram (OGI) and Tilray (TLRY) both expanding German export volumes. A US Schedule III determination would significantly increase the probability of subsequent bilateral trade framework development, given that Schedule III status would bring the US into greater alignment with international drug convention frameworks that Canadian and European regulators operate under.
Conclusion
Thursday’s rescheduling catalyst signal represents the kind of near-term inflection point that cannabis sector investors have been positioned for across multiple years of regulatory delay. The September–October final rule publication window, if it holds, would establish a Q4 2026 rescheduling catalyst that arrives coincident with Q3 earnings season — a confluence that creates a meaningful potential re-rating event for well-capitalized, cash-flow-positive MSOs and LPs positioned to benefit most directly from 280E normalization. The prudent institutional framework for the current moment remains one of monitored positioning rather than speculative sizing — the regulatory timeline has slipped before, and the legal challenge risk from anti-legalization advocacy groups is non-trivial. But the directional signal from this week’s OLC review progress is unambiguously constructive for the sector’s near-term catalyst horizon.